Who We Are

Anand qualified as a chartered accountant with Arthur Andersen in 2000. He worked in their Corporate Finance department for seven years, specializing in private equity and corporate transactions, before joining the CBPE Capital team.

Anand has a degree in Mathematics from the University of Nottingham.

Ceri has spent much of her career at Simbec-Orion and was appointed Managing Director, Clinical Pharmacology in December 2019. Ceri has over 20 years’ experience in operations, project management and team leadership in early phase clinical research.

Ceri is also a member of the Senior Management Team and has overall responsibility for the Clinical Pharmacology and Laboratory Services divisions at Simbec-Orion. Ceri’s responsibilities include operations, strategy execution and for ensuring client expectations are met by the team.

In 1997, Fabrice and Dr Alan Irvine, founded Orion Clinical Services Ltd, an international CRO operating internationally and specialised in Rare and Orphan diseases, oncology and other indications with high medical need.  In 1994, Fabrice founded Fournier Laboratories, a medium-size French pharmaceutical company and their UK International Clinical Development Unit, specialised in Gene Therapy and Immunotherapy. Previously, he was one of the directors of an international CRO based in Paris.

Fabrice has been the CEO of Simbec-Orion since November 2019, before which he was appointed COO of Simbec-Orion upon completion of the merger of Simbec Research and Orion Clinical Services in June 2014.

John joined Simbec-Orion as Chief Financial Officer in 2019. Having qualified as a Chartered Account with KPMG, for over ten years, he specialised in Transaction Service performing financial due diligence for corporates and venture capitalists. After KPMG, John joined GKN plc, a FTSE 100 company where he enjoyed eight years in senior financial and operational roles in Corporate Finance and the Driveline Division, including four years living in Singapore as GKN Driveline’s Regional M&A Director and Regional Finance Director of its £350m turnover Division.  John has extensive experience of working in Asia and Japan.

John served for nine years as the Group Finance Director of Europe’s leading fire alarm and carbon monoxide detector business, FireAngel Safety Technology Group plc and led the Group’s IPO on AIM in April 2014.  Prior to listing on AIM, John led a successful bid defence against a hostile takeover from a Fortune 500 company.

Anita joined the board of Simbec-Orion in 2019 and has over 30 years of global business expertise.

Previously, she served as an Executive Officer and Senior Vice-President of PAREXEL. Anita’s broad leadership experience includes effective strategy development, governance, risk management, business start-up and process transformation. She has set up operations and business units across the world and has significant business, acquisition, integration and change-management expertise. Anita emphasizes integrity, strategy and excellence, as well as culture and talent development for diversity.

Anita holds an M.A. Honours degree in Psychology from St. Andrews University and a D.Phil. in Experimental Psychology from St. John’s College, Oxford.

Adam joined CBPE Capital as an Investment Manager in 2018, and shortly after he joined the board of Simbec-Orion.

Adam was formally part of Kester Capital where he focused on primary buyouts in the UK lower mid-market. Before Kester, he was an Analyst at Hawkpoint which is now part of Cancaccord Genuity. Adam has an MSc in Physics from the University of Cambridge.

Jim was appointed CIO of Simbec-Orion in January 2019 to leverage technology, data, people and process as strategic enablers to deliver Simbec-Orion’s growth strategy.

Most recently Jim was VP Technology for the Michael & Susan Dell Foundation responsible for delivering the overall vision and operational execution for the Foundation’s technology strategy in order to accomplish their philanthropic goals globally.

As VP Technology for IQVIA Jim was focused on local UK and Global technology delivery in Commercial and Clinical Business Units, managing annual IT investment strategy and creating the go-to-market strategy for the IQVIA Infosario product at its inception. For 7 years up to IPO in 2013, Jim was a key part of the leadership team that grew the IT group from 300 to over 1000 employees, won several business innovation awards and was consistently recognized as one of the ‘Best 100 Places to Work’ by Computer World.

Melissa joined Simbec-Orion in April 2019 as Chief Commercial Officer. Melissa previously headed the commercial group at Synexus Clinical Research whilst it was an independent private equity-held company through to its successful acquisition by PPD and subsequent integration.

Melissa has led commercial teams at Synexus, Premier Research and Kendle International through significant growth and expansion periods meeting strategic & corporate goals.

Melissa has significant business development & account management experience from her tenure at IQVIA. Melissa started her career within clinical operations at Innovex, which was later acquired by IQVIA in 1996.

Enrique joined Simbec-Orion in September 2020 as Senior Director, Group Head of Quality Assurance. Enrique has over 24 years’ experience in Clinical Research from early to late phase trials.  Having studied for a BA in Chemistry at the University of Pennsylvania and an MSc in Chemical Research at Imperial College London Enrique joined the industry as a CRA and has spent the last 20 years in Quality Assurance within Global CROs.

Enrique has a passion for developing quality systems whilst promoting a culture of quality across diverse global organisations.  He has significant experience in leading quality assurance teams globally, working in partnership with operations to implement risk-based strategies, simplify process, and embed fit-for purpose quality systems that focus on patient safety, data integrity and regulatory compliance.

Enrique has held senior QA roles at Covance, i3 Research, Pharm-Olam International and Medpace.

Ana joined Simbec-Orion in 2019 as Group Head of Human Resources, before being appointed as Chief People Officer in December 2019. At Simbec-Orion, Ana is responsible for leading the function to support the end-to-end employee life cycle including talent acquisition (recruitment), performance management, learning and development, compensation and employee relations.

Prior to joining Simbec-Orion, Ana was head of HR at AstraZeneca between 2015-2019, prior to which she worked primarily as an HR Business Partner between 2007-2014 leading for restructuring, change and transformation at AstraZeneca.

Ana graduated from Reading University with 2:1 LLB (Hons) Law in 2000.

Ceri has spent much of her career at Simbec-Orion and was appointed Managing Director, Clinical Pharmacology in December 2019. Ceri has over 20 years’ experience in operations, project management and team leadership in early phase clinical research.

Ceri is also a member of the Senior Management Team and has overall responsibility for the Clinical Pharmacology and Laboratory Services divisions at Simbec-Orion. Ceri’s responsibilities include operations, strategy execution and for ensuring client expectations are met by the team.

In 1997, Fabrice and Dr Alan Irvine, founded Orion Clinical Services Ltd, an international CRO operating internationally and specialised in Rare and Orphan diseases, oncology and other indications with high medical need.  In 1994, Fabrice founded Fournier Laboratories, a medium-size French pharmaceutical company and their UK International Clinical Development Unit, specialised in Gene Therapy and Immunotherapy. Previously, he was one of the directors of an international CRO based in Paris.

Fabrice has been the CEO of Simbec-Orion since November 2019, before which he was appointed COO of Simbec-Orion upon completion of the merger of Simbec Research and Orion Clinical Services in June 2014.

John joined Simbec-Orion as Chief Financial Officer in 2019. Having qualified as a Chartered Account with KPMG, for over ten years, he specialised in Transaction Service performing financial due diligence for corporates and venture capitalists. After KPMG, John joined GKN plc, a FTSE 100 company where he enjoyed eight years in senior financial and operational roles in Corporate Finance and the Driveline Division, including four years living in Singapore as GKN Driveline’s Regional M&A Director and Regional Finance Director of its £350m turnover Division.  John has extensive experience of working in Asia and Japan.

John served for nine years as the Group Finance Director of Europe’s leading fire alarm and carbon monoxide detector business, FireAngel Safety Technology Group plc and led the Group’s IPO on AIM in April 2014.  Prior to listing on AIM, John led a successful bid defence against a hostile takeover from a Fortune 500 company.